Oncology & Cancer
Widely used kidney cancer drugs can't stop recurrence
Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life ...
Mar 10, 2016
0
0
